Category: Blogroll
New hedgehog inhibitor: zerumbone
At any rate, the researchers found that, like cyclopamine, zerumbone, the substance I am interested in right now, antagonizes Hh. One big difference, though. Cyclopamine, as I mentioned, targets Smo, an earlier stage of Hh, whereas zerumbone (and a few of the other compounds examined in this study) affects the final stage of Hh, which is called GLI1 (the acronym stands for “glioma-associated oncogene homolog 1,” aren’t you glad you know that? ).
The researchers tested 94 compounds from our natural product library, including terpenoids, flavonoids, phenylpropanoids, their glycosides and bisindole alkaloids […] and identified two sesquiterpenes and four bisindole alkaloids as inhibitors of GLI-mediated transcription. So they found six compounds that will inhibit GLI1, including zerumbone.
One last bit of intriguing news, though: zerumbone also inhibits the Epstein-Barr virus…see: http://tinyurl.com/4lbh92 Well, it’s getting late, and I must get off this computer.
I can tell that this is going to be a long hedgehog weekend!
Healthy writing
And read this: Expressive writing refers to writing about one’s deepest thoughts and feelings about life experiences. Studies have shown that the practice can benefit people with health conditions such as asthma, arthritis, pelvic pain and cancer. The benefits, in some studies, have included physical ones, like reduced pain and improved immune function, the researchers explain in the journal The Oncologist.
Improved immune function…!
And how long was this writing session? Twenty minutes. Ehhhh? That’s it??? That means that my quality of life should be even better than that of a groundhog living in a field of daisies!
Hold on to your socks!
Omega-3 and angiogenesis
But what about n-6 fatty acids? The abstract tells us that n-6 PUFAs stimulate angiogenesis. Does that make n-6 one of the bad guys? That’s what I thought, at first. But no, we need both these fatty acids in order to be healthy, so eliminating n-6s from our diet would be a very VERY bad move.
What we lack is BALANCE between the two omegas. Read this: In terms of the consequences for human health, it has been shown that Japanese who migrated to the United States and acquired the local dietary habits leading to an increase in the dietary n-6/n-3 PUFA ratio of 16:1 resulted in health problems in the migrants similar to those that already existed in the local population. Sixteen to one! That’s astounding. Even more astounding: the ideal balance should be 1:1, at the most 4:1. But the average North American diet, and probably European by now, ranges from 11:1 to 30:1. Yikes!
According to Andrew Weil, M.D., This dietary imbalance may explain the rise of such diseases as asthma, coronary heart disease, many forms of cancer, autoimmunity and neurodegenerative diseases, all of which are believed to stem from inflammation in the body. The imbalance between omega-3 and omega-6 fatty acids may also contribute to obesity, depression, dyslexia, hyperactivity and even a tendency toward violence.(see: http://tinyurl.com/4s32fc; see also: http://tinyurl.com/565h8n).
Now, what happens when we ingest n-3s and n-6s? They get converted by so-called PUFA bioconversion enzymes. Otherwise, these fatty acids would not be of any use to us at all. The researchers state that their findings suggest that n-6 and n-3 PUFAs compete for enzymes involved in PUFA biotransformation. It is widely believed that PUFA bioconversion enzymes have a greater affinity for n-3 PUFAs so that their biotransformation is favored when the dietary n-3 PUFA intake is high. This simply means that the two omegas compete for the attention of these bioconversion enzymes, and n-3s happen to be the winners.
At any rate, our bodies are not able to produce these fatty acids from scratch, and in fact that is why they are called "essential" (essential for health, but cannot be made inside the body), so we need to get them from our food.
Dietary sources of n-3s: mainly cold water fish such as salmon, herring, anchovies, but be careful about the potential presence of heavy metals, PCBs and dioxin (!); also, but to a lesser degree, flax, pumpkin seeds, walnuts, pecans, butternuts, nut oils, as well as the seeds of: chia sage, kiwi, lingonberry, black raspberry. For more info: http://en.wikipedia.org/wiki/Omega_3. By the way, today I learned that mercury does not get stored in fish oil (only in the tissue). How about that? I also learned that some manufacturers are able to purify fish oil via molecular distillation, which increases the cost, but who wants to be swallowing dioxin or pesticides, after all? I would rather pay more for a high quality product. So, do your research, watch what you buy, and don’t go for el cheapo.
Dietary sources of n-6s: poultry, eggs, cereals, whole-grain breads, baked goods, most plant-based cooking oils (sunflower, corn etc.), nuts, borage oil. See also: http://en.wikipedia.org/wiki/Omega_6
Disappearing photos
Hi everyone! My blog photos have disappeared. All of them. Swallowed up by cyberspace or by the vengeful Google Ads. Gulp! I have gotten in touch with the Healthblogs manager, and am sure that order will be restored as soon as she reads the message (it’s still the middle of the night in the U.S., so she’s still asleep for sure). Anyway, no worries.
Yesterday I received more information concerning the DMAPT clinical trial. The UK trial is open only to UK citizens. Well, that takes care of that!
I now do know where the trial is going to be held, though: at the University of Cardiff, under Dr. Alan Burnett, Head of the Haematology Department. As of today, though, there is no information on the trial on the U. of Cardiff website. The waiting game continues.
I am working on a post, so off I go!
Cheeky!
Nanocrud
I confess to being a bit amused, I admit (apart from the rabbit business…see below). This morning I read a couple of Science Daily updates where I found two conflicting items. The first (http://tinyurl.com/5p4lzn), dated April 3, was about the potential risks involved in nanotechnology. It just so happens that yesterday I added a link to a study on nanocurcumin sent to me by a blog reader (thanks!). See under "useful links."
At any rate, the Science Daily article discusses a University of Oregon chemist’s concern about the potential hazards and lack of information concerning nanotechnology.
An excerpt ("he" is the UO chemist, by the way): Nanomaterials are complex, as are their interactions with biological organisms and the environment. While microscopically sized, they come in all sizes, shapes and compositions. "To confound the situation further," he writes, "the methods of production are still immature for most materials, often resulting in batch-to-batch variability in composition and purity." Impurities, he says, are hard to detect, difficult to extract and may obscure the real effects of nanomaterials. Nanoimpurities? Yikes!
Interestingly, this scientist is pushing for a green chemistry approach, which simplifies purification processes. Well, I am certainly all in favour of solving problems before they occur, and using an environmentally friendly approach makes a lot of sense to me.
Now for the second article. published on the following day (http://tinyurl.com/6qzpmv). It discusses the effect of nanotechnology on tumours. Unlike the University of Oregon piece, this article talks exclusively about the benefits of nanotechnology. As follows.
A group of researchers at the Washington University School of Medicine (St. Louis) tested a powerful drug directly on tumors in rabbits (aaagh! ) using drug-coated nanoparticles. They found that a drug dose 1,000 times lower than used previously for this purpose markedly slowed tumor growth. "Many chemotherapeutic drugs have unwanted side effects, and we’ve shown that our nanoparticle technology has the potential to increase drug effectiveness and decrease drug dose to alleviate harmful side effects," says lead author Patrick M. Winter, Ph.D., research assistant professor of medicine and biomedical engineering.
By the way, these nanoparticles contained a fungal toxin called fumagillin, which has been shown to be an effective cancer treatment, so the article states, in human clinical trials in combination with other drugs. The process whereby the tumours’ growth was slowed down is interesting: the nanoparticles latched on to sites of blood vessel proliferation and released their fumagillin load into blood vessel cells. Fumagillin blocks multiplication of blood vessel cells, so it inhibited tumors from expanding their blood supply and slowed their growth.
Aha, so fumagillin inhibits angiogenesis…very interesting. I will have to have a closer look at this toxin at some point.
Well, nanotechnology is interesting on many levels, but I have to admit that the issue of nanocrud (I just coined this term, you may use it with my permission…) does make me wary. I guess I won’t be testing nanocurcumin any time soon…
DMAPT response
Well, no DMAPT trial for yours truly. I received an answer just now and, in a nutshell, I was advised, given my current (good) clinical status, to wait and see how the initial trials work out. This could take a couple of years, I was told.
I would like to note that the reply I received was very straightforward. And very kind. Much appreciated.
I will certainly be following the trials carefully…and at least I tried.
DMAPT update
This morning I received a Google Alert about DMAPT, which, as you may recall, is the parthenolide analogue (from feverfew, see image on the left) that targets leukemic stem cells and will be tested soon (I hope!) in clinical trials. For more info on this topic, see my parthenolide/DMAPT page on the right-hand of your screen.
The first clinical trial will begin in England. If successful, it will be followed by others in the States. Apparently, there have been some bureaucratic hurdles (such as regulatory approval), but patient selection in the UK may begin this month.
I want to see if I might qualify for this trial, so this morning I decided to write to the chief investigators to obtain more information, if possible.
I have already sent off one e-mail and will write another, more detailed one, later on today. I hope to be a frequent flyer to the UK soon! Fingers crossed!
Late morning update: I just sent a query to the senior author of the DMAPT "Blood" study. Now I just have to sit back and wait.